S. Veronese

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Silvio Marco Veronese, S M Veronese, S.m. Veronese, S Veronese, Silvio M Veronese, Silvio Veronese, S. Veronese
Publication record
145 papers · 12,146 citations · H-index 41

PAPERS

Repotrectinib Overcomes F2004V Resistance Mutation in ROS1-Rearranged NSCLC: A Case Report
20235 citationsauthor #10
72P Molecular characterization of advanced primary cardiac sarcomas
20231 citationsauthor #17
RARE CAUSES OF ACUTE CORONARY SYNDROME: THE JAK2 V617F MUTATION POSITIVE MYELOPROLIFERATIVE NEOPLASMS. A cardio-hematological perspective.
20221 citationsauthor #6
Evolutionary Portrait of Adult Core-Binding Factor Leukemia Patients Treated with a Continuation Therapy with Midostaurin: Preliminary Results
20220 citationsauthor #20
Concomitant JAK2 V617F mutation and rare e1a2 BCR-ABL1 transcript isoform in a patient with Myeloproliferative Neoplasm
20221 citationsauthor #10
Acute Promyelocytic Leukemia with del(6)(p22) and Atypical bcr2 PML::RARA Fusion Transcript: A Case Report
20223 citationsauthor #11
Prevalence and outcome of patients with acute myocarditis and positive viral search on nasopharyngeal swab
202113 citationsauthor #12
Real-World Data on NGS Diagnostics: a survey from the Italian Society of Pathology (SIAPeC) NGS Network
202113 citationsauthor #15
Rapid Detection and Quantification of Mycobacterium tuberculosis DNA in Paraffinized Samples by Droplet Digital PCR: A Preliminary Study
202112 citationsauthor #15
New‐Onset Antibodies to Platelet Factor 4 Following Liver Transplantation From a Donor With Vaccine‐Induced Thrombotic Thrombocytopenia
20217 citationsauthor #9
Genetic Landscape and Clonal Evolution Patterns of CEBPA-Mutated Acute Myeloid Leukaemia Based on Next-Generation Sequencing: A Retrospective Analysis
20211 citationsauthor #3
BCR/ABL1 fluorescence in situ hybridization fusion signals on both copies of chromosome 22 in a Philadelphia-masked chronic myeloid leukemia case: implication for the therapy
20212 citationsauthor #8
Liquid Biopsy for Small Cell Lung Cancer either De Novo or Transformed: Systematic Review of Different Applications and Meta-Analysis
202121 citationsauthor #6
Enasidenib, an Oral Therapy in Mutant IDH2 Relapsed/Refractory Acute Myeloid Leukemia: A Real-Life Single Center Experience
20202 citationsauthor #9
Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL.
2020103 citationsauthor #43
Prospective Evaluation of a Continuation Therapy with Midostaurin in Adult Patients with Core-Binding Factor Leukemia and Integrated Genetic Analysis: A Multi Center Phase II Study. Preliminary Results
20200 citationsauthor #19
Concurrent Small-Cell Transformation and Emergence of Trans-C797S and T790M Mutations Under Sequential Treatment With EGFR Inhibitors in Lung Adenocarcinoma.
20194 citationsauthor #13
TRKA expression and NTRK1 gene copy number across solid tumours
201813 citationsauthor #13
Single‐center outbreak of Pneumocystis jirovecii pneumonia in heart transplant recipients
201819 citationsauthor #7
Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta‐Analysis
2017119 citationsauthor #7
No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy
201722 citationsauthor #15
Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes
201728 citationsauthor #21
(210) – First Outbreak of Pneumocystis jirovecii Pneumonia in Heart Transplantation Recipients
20170 citationsauthor #7
A Case of Blastic Plasmacytoid Dendritic Cell Neoplasm Extensively Studied by Flow Cytometry and Immunohistochemistry
20176 citationsauthor #8
Mutation enrichment next-generation sequencing for quantitative detection of KRAS mutations in urine cell-free DNA from patients with advanced colorectal and other cancers.
20170 citationsauthor #12
Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patient
201713 citationsauthor #5
1716PTRKA expression and NTRK1 gene copy number across solid tumors
20170 citationsauthor #11
Abstract CT005: Final results of the HERACLES trial in HER2-amplified colorectal cancer
201721 citationsauthor #18
P PIK 3 CA mutation and PDL 1 expression in lung squamous cell carcinoma surgically resected
20170 citationsauthor #20
Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers
201750 citationsauthor #11
Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patient.
201720 citationsauthor #5
Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience
201716 citationsauthor #27
Bing Neel Syndrome in a Previously Untreated Patient With Waldenström's Macroglobulinemia: Contribution of MYD88 L265P Mutation on Cerebrospinal Fluid.
201611 citationsauthor #4
D01*Final Results of the HERACLES trial in HER2 amplified colorectal cancer
201614 citationsauthor #18
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
2016839 citationsauthor #26
Reappraising Immunoglobulin Repertoire Restrictions in Chronic Lymphocytic Leukemia: Focus on Major Stereotyped Subsets and Closely Related Satellites
20161 citationsauthor #23
Monitoring clonal evolution and resistance to EGFR blockade in the blood of metastatic colorectal cancer patients
201610 citationsauthor #21
Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer
20163 citationsauthor #4
c.428T > C (p.V143A) homozygous mutation in TP53 gene as a possible mechanism of resistance to trastuzumab therapy in gastric cancer
20162 citationsauthor #6
Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations.
201583 citationsauthor #18
Abstract 916: The molecular landscape of colorectal cancer cell lines unveils clinically actionable targets
20150 citationsauthor #6
Two cases of elevated tryptase in abdominal aortic aneurysm.
20152 citationsauthor #3
The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets
2015279 citationsauthor #11
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
2015952 citationsauthor #21
Epitope Recognition in the Human–Pig Comparison Model on Fixed and Embedded Material
201512 citationsauthor #7
Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.
201546 citationsauthor #5
Germ Cell Tumors Overexpress the Candidate Therapeutic target Cyclin B1 Independently of p53 function
20153 citationsauthor #4
Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial.
201560 citationsauthor #17
Raise and decline of KRAS mutant clones in colorectal cancers (CRCs) treated with multiple rounds of anti-EGFR antibodies.
20150 citationsauthor #11
CLL with Mutated IGHV4-34 Antigen Receptors Is Clinically Heterogeneous : Antigen Receptor Stereotypy Makes the Difference
20150 citationsauthor #20
Immunocytochemical Detection ofProgesterone Receptors* A Studyina Patient WithPrimary Pulmonary Hypertension
20150 citationsauthor #1
Solitary thyroid metastasis from colon cancer: fine-needle aspiration cytology and molecular biology approach.
20155 citationsauthor #6
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study
2015284 citationsauthor #26
Alka-372-001: First-in-human, phase I study of entrectinib - an oral pan-trk, ROS1, and ALK inhibitor - in patients with advanced solid tumors with relevant molecular alterations.
201558 citationsauthor #11
Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer
2015132 citationsauthor #18
Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
2015123 citationsauthor #21
E11Pooled analysis of clinical outcome of patients with chemorefractory metastatic colorectal cancer treated within clinical studies based on individual molecular alterations at Niguarda Cancer Center
20150 citationsauthor #17
KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy
201583 citationsauthor #15
Therapeutic dual inhibition of HER2 pathway for metastatic colorectal cancer (mCRC): The HERACLES trial.
201516 citationsauthor #17
Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer
201575 citationsauthor #8
Phase 1 open label, dose escalation study of RXDX101, an oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations.
201438 citationsauthor #12
Charting Unique Signatures of Somatic Hypermutation Amongst Chronic Lymphocytic Leukemia Patients Expressing IGHV4-34 Clonotypic B Cell Receptors
20140 citationsauthor #12
448PDRXDX-101, AN ORAL PAN-TRK, ROS1, AND ALK INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS WITH RELEVANT MOLECULAR ALTERATIONS.
20149 citationsauthor #12
Clinical Impact of Stereotyped Antigen Receptors in Chronic Lymphocytic Leukemia
20140 citationsauthor #18
Cancer Therapy : Preclinical SynergisticAntitumorActivityofCetuximabandNamitecan in Human Squamous Cell Carcinoma Models Relies on Cooperative Inhibition of EGFR Expression and Depends on High EGFR Gene Copy Number
20140 citationsauthor #3
Not All IGHV3-21 CLL Are Equal : Subset #2 Displays a Distinctive Clinicobiological Profile with Remarkable Similarities to Subset #169, its Close Immunogenetic Relative
20140 citationsauthor #18
Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study.
2014118 citationsauthor #19
The TPM3‐NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition
2014148 citationsauthor #26
Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL.
2013198 citationsauthor #13
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.
2013627 citationsauthor #17
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.
2013477 citationsauthor #5
KRAS gene amplification in colorectal cancer and impact on response to EGFR‐targeted therapy
2013174 citationsauthor #13
Synergistic Antitumor Activity of Cetuximab and Namitecan in Human Squamous Cell Carcinoma Models Relies on Cooperative Inhibition of EGFR Expression and Depends on High EGFR Gene Copy Number
20138 citationsauthor #3
Should a positive direct antiglobulin test be considered a prognostic predictor in chronic lymphocytic leukemia?
201312 citationsauthor #5
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
20121,792 citationsauthor #14
The first Caucasian patient with p.Val122Ile mutated-transthyretin cardiac amyloidosis treated with isolated heart transplantation
201222 citationsauthor #8
Contents Vol. 102, 2012
20120 citationsauthor #58
TAILOR: A phase III trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild-type (wt) EGFR.
201250 citationsauthor #9
A quantitative-PCR protocol rapidly detects αGAL deletions/duplications in patients with Anderson-Fabry disease.
20126 citationsauthor #5
A Case of Compound Mutations in the MYBPC3 Gene Associated with Biventricular Hypertrophy and Neonatal Death
201233 citationsauthor #8
P2.08 Emergence of Kras Mutations and Acquired Resistance to Anti Egfr Therapy in Colorectal Cancer
20123 citationsauthor #14
TAILOR: Phase III trial comparing erlotinib with docetaxel in the second-line treatment of NSCLC patients with wild-type (wt) EGFR.
201247 citationsauthor #10
What Numbers Don't Say: Immunogenetic Evidence Shows That High-Count MBL Resembles Rai 0 CLL While Low-Count MBL Does Not.
20120 citationsauthor #13
Standardization of EGFR FISH in colorectal cancer: Results of an international, interlaboratory reproducibility ring study.
20114 citationsauthor #3
4.4 ARSD Is a New Biomarker Associated with IgVH, ZAP-70, and Disease Progression in CLL
20110 citationsauthor #9
Microarray Gene Expression Signature Indicates ARSD As a New Marker Associated with Igvh Mutational Status, ZAP-70 and Disease Progression in CLL,
20111 citationsauthor #9
EGFR FISH analysis in colorectal cancer as a tool in selecting patients for antiEGFR monoclonal antibodies therapy
20111 citationsauthor #3
Gene expression profiling identifies ARSD as a new marker of disease progression and the sphingolipid metabolism as a potential novel metabolism in chronic lymphocytic leukemia
201129 citationsauthor #9
Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study
201145 citationsauthor #3
IGHV1-69/D3-16/J3 SUBSET 6 IS ASSOCIATED WITH INDOLENT DISEASE COURSE OF EARLY STAGE CLL (RAI 0) INDEPENDENT OF UNMUTATED STATUS
20101 citationsauthor #9
[Genomics in cardiological clinical practice: from the individual response to drug therapy and monogenic cardiovascular disorders].
20102 citationsauthor #3
Unmutated IGHV1-69/D3-16/J3 Stereotyped HCDR3 Rearrangements (Subset 6) Are Associated with Indolent Disease Course and Have Outcome Independent of Mutational Status In Early Stage CLL (Rai 0)
20102 citationsauthor #8
Role of cetuximab in the treatment of patients with NSCLC: are we throwing out the baby with the bath water?
20101 citationsauthor #4
Zap-70 EXPRESSION and Igvh Mutational Status as Markers for Gene EXPRESSION Signature IN B-CLL PATIENTS for Prognostic Classification.
20090 citationsauthor #7
ZAP-70, IgVh, and cytogenetics for assessing prognosis in chronic lymphocytic leukemia
200918 citationsauthor #6
Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer
2009284 citationsauthor #12
Abstract B229: Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer
20091 citationsauthor #13
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.
2009784 citationsauthor #4
Molecular characterization of post‐transplant lymphoproliferative disorders of donor origin occurring in liver transplant recipients
200941 citationsauthor #4
Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer.
2008238 citationsauthor #3

TIMELINE

1983 1 citations

1987 1 citations

1989 17 citations

1992 5 citations

1993 2 citations

1995 18 citations

1996 174 citations

1997 0 citations

1998 97 citations

2000 188 citations

2002 88 citations

2003 257 citations

2004 54 citations

2005 1,012 citations

2006 149 citations

2007 1,177 citations

2008 323 citations

2009 1,128 citations

2010 6 citations

2011 80 citations

2012 1,953 citations

2013 1,496 citations

2014 313 citations

2015 2,213 citations

2016 880 citations

2017 295 citations

2018 32 citations

2019 4 citations

2020 105 citations

2021 69 citations

2022 5 citations

2023 6 citations

S. Veronese

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT